Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Henan Taloph Pharmaceutical Stock Co's quarterly market cap
increased
from Sep. 2025 (¥3,725 Mil) to Dec. 2025 (¥3,776 Mil) and
increased
from Dec. 2025 (¥3,776 Mil) to Mar. 2026 (¥4,057 Mil).
Henan Taloph Pharmaceutical Stock Co's annual market cap
declined
from Dec. 2023 (¥3,518 Mil) to Dec. 2024 (¥2,921 Mil) but then
increased
from Dec. 2024 (¥2,921 Mil) to Dec. 2025 (¥3,776 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Henan Taloph Pharmaceutical Stock Co's Enterprise Value for Today is ¥5,018 Mil.
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Henan Taloph Pharmaceutical Stock Co Market Cap Related Terms
Henan Taloph Pharmaceutical Stock Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Taloph Pharmaceutical Stock Co Market Cap Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Henan Taloph Pharmaceutical Stock Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Henan Taloph Pharmaceutical Stock Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Henan Taloph Pharmaceutical Stock Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Henan Taloph Pharmaceutical Stock Co's Market Cap falls into.
Henan Taloph Pharmaceutical Stock Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) has a Market Cap of ¥4,167 Mil as of Jul. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors. According to the industry distribution chart, Henan Taloph Pharmaceutical Stock Co ranks #350 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 34.2%.
Is Henan Taloph Pharmaceutical Stock Co's Market Cap too high?
Henan Taloph Pharmaceutical Stock Co's current Market Cap is ¥4,167 Mil. Based on the distribution chart, Henan Taloph Pharmaceutical Stock Co ranks #350 out of 1023 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Henan Taloph Pharmaceutical Stock Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Henan Taloph Pharmaceutical Stock Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Henan Taloph Pharmaceutical Stock Co ranks #350 out of 1023 companies for Market Cap. This puts Henan Taloph Pharmaceutical Stock Co in the upper half of its industry. The industry median Market Cap is 216.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 216.46, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 216.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Henan Taloph Pharmaceutical Stock Co's current Market Cap is ¥4,167 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Taloph Pharmaceutical Stock Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co (SHSE:600222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.91, compared to a current price of ¥7.45 — trading 51.7% above its estimated fair value. The current Market Cap is ¥4,167 Mil. Henan Taloph Pharmaceutical Stock Co's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Henan Taloph Pharmaceutical Stock Co (SHSE:600222), the current Market Cap is ¥4,167 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued.
The current stock price of ¥7.45 is trading 51.7% above its estimated GF Value™ of ¥4.91.
GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.
Key valuation signals for SHSE:600222:
Market Cap: ¥4,167 Mil
GF Value™: ¥4.91 vs. price of ¥7.45 (51.7% above fair value)
No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henan Taloph Pharmaceutical Stock Co Business Description
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
58GF Score
Get the complete analysis for SHSE:600222
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600222 has been successfully added to your 
